
View larger version (53K):
[in this window]
[in a new window]
|
Fig. 5. An SBMO prevents mRNA maturation and causes developmental abnormalities
in embryos. (A) Schematic showing oligo binding site and RT-PCR
demonstrating inhibition of mRNA maturation by the SBMO. Both pseudoalleles
are affected. Genomic DNA template was used as a positive control for
unspliced product. (B) An alternative morpholino, targeting the splice
donor site, does not efficiently inhibit mRNA maturation. (C) RTPCR
analysis of XBra and FGF8 expression in animal caps depleted
of FoxI1e and treated with 1 µg/ml Activin A. SBMO-injected animal caps
showed levels of mesoderm induction similar to uninjected caps. (D,E)
Embryos injected animally at the twocell stage with a dose range of SBMO.
There were dose-dependent abnormalities in development, shown at the neurula
stage (stage 19, D) and in tailbud stage embryos (stage 27, E). (F)
Epidermal cytokeratin, slug, sox-2, FoxG1 (BF-1) and
Xlhbox6 are all reduced at stage 23. E. keratin, slug and
sox-2 are partially rescued by 50 pg FoxI1e mRNA. (G)
Xbra, Xwnt-8 and chordin are unaffected by SBMO injection at
stage 11.5.
|